NASDAQ NMS - GLOBAL MARKET · GANX
+1.01% · +$0.0200 · Vol 277.5K
Market closed · last close 4:00 PM ET · price as of 17:09:33 ET
Gain Therapeutics Inc

Gain Therapeutics Inc

Biotechnology
$2.00
Card
Relationship Map

Veridion Score

BETALOW CONF · 6/6 factorsMethodology
GANX
Gain Therapeutics Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GANX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GANX catalysts
About Gain Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2021
Employees
21
Country
US

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.00
Day high
$2.04
Day low
$1.98
Previous close
$1.98
52W high
$4.18
-52.15% from high
52W low
$1.58
16% of range
Market cap
$87.5M
EPS
$-0.5800
Beta
2.34
Shares out
43.6M
Volume
277.5K
0.49× rel vol
Avg volume
567K
VWAP
$2.01
Price history computed in-house
1W
-1.96%
1M
+14.29%
3M
+9.89%
1Y
+1.52%
YTD
-37.89%
SMA 50 $1.83 · above
SMA 200 $2.20 · below
52W position 16%

GANX overview

Veridion Score
59
Registered · 2026-08-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GANX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GANX Form 4 filings
Public disclosures

Congress activity in GANX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for GANX in the cached public ledger.

Federal contracts

GANX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GANX in this window.
Lobbying spend

GANX lobbying filings, year to date.

Registered lobbying filings matched to Gain Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GANX in this window.
Loading news for GANX
Analyst ratings
Sovereign unlock shows live analyst consensus for GANX.
Options
Sovereign unlock shows live options positioning for GANX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.